People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centry Pharma, Inc. | — | Pharmaceuticals | Series A | $11.3M | $234.3M | 2021 |
| Scinai Immunotherapeutics Ltd. | — | Pharmaceuticals | Seed | $3.0M | $10.5M | 2023 |
Uri Ben Or at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Uri Ben Or on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ron Bentsur | 1 | 4 |
| Matthew Kaplan | 1 | 3 |
| Kenneth Hoberman | 1 | 3 |
| Mark Germain | 1 | 2 |
| Yael Margolin | 1 | 2 |
| James Oliviero | 1 | 2 |
| Enrique Poradosu | 1 | 2 |
| Shay Shemesh | 1 | 2 |
| Adi Raviv | 1 | 1 |
| Samuel Moed | 1 | 1 |
| Jay Green | 1 | 1 |
| Avner Rotman | 1 | 1 |
| Elad Mark | 1 | 1 |
| Morris Laster | 1 | 1 |
| Amir Reichman | 1 | 1 |
| Tamar Ben-Yedidia | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.